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Abstract 
Background: Previous studies have reported that in patients with heart failure, an increased value 
of red cell distribution width (RDW) is associated with adverse outcomes. Nonetheless, data regarding 
the association between RDW values and long-term mortality in patients with left ventricular systolic 
dysfunction (LVSD) are lacking. The aim of this investigation was to examine the relationship between 
mortality and RDW in patients with ischemic and non-ischemic LVSD. 
Methods: Under analysis was 1734 patients with a left ventricular ejection fraction (LVEF) ≤ 35% 
of whom were hospitalized between 2009 and 2013. Patients were divided into three groups based on 
RDW tertiles. Low, medium and high tertiles were defined as RDW ≤ 13.4%, 13.4% < RDW ≤ 14.6% 
and RDW > 14.6%, respectively.
Results: There was a stepwise relationship between RDW intervals and comorbidities. Patients with 
the highest RDW values were older and more often diagnosed with anemia, diabetes, atrial fibrillation 
and chronic kidney disease. The main finding of our analysis was the presence of an 8-fold increase in 
all-cause mortality in the entire cohort between high and low RDW tertile. Cox hazard analysis identi-
fied RDW as an independent predictive factor of mortality in all patients (HR 2.8; 95% CI 2.1–3.8; 
p < 0.0001) and in subgroups of patients with ischemic (HR 2.8; 95% CI 2.0–3.9; p < 0.0001) and 
non-ischemic (HR 3.3; 95% CI 2.01–5.5; p < 0.0001) LVSD. 
Conclusions: The highest RDW tertile was independently associated with higher long-term mortality 
compared with low and medium tertiles, both in all patients with a LVEF ≤ 35% and in subgroups of 
patients with ischemic and non-ischemic LVSD. (Cardiol J 2018; 25, 3: 377–385)
Key words: red cell distribution width, heart failure, mortality, iron metabolism  
disorders, ventricular ejection fraction
Introduction
Red blood cell distribution width (RDW) re-
flects variability in the size of circulating erythro-
cytes and is a marker of anisocytosis [1]. In recent 
years, anisocytosis has emerged as a prognostic 
biomarker in cardiovascular disease. Numer-
ous studies have noted the relationship between 
RDW values and adverse clinical outcomes in the 
setting of coronary artery disease (CAD), includ-
ing patients undergoing percutaneous coronary 
interventions in the course of stable coronary 
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artery disease and patients with acute coronary 
syndromes (ACS) [2, 6–8]. 
The pioneering work assessing the role of 
RDW in heart failure (HF) was published by Fel-
ker et al. [9]. The authors noted that increased 
RDW was a novel, strong independent predictor of 
higher morbidity and mortality among patients with 
chronic HF included in the Candesartan in Heart 
Failure: Assessment of Reduction in Mortality and 
Morbidity (CHARM) study. The authors confirmed 
this finding in the Duke Databank for Cardiovas-
cular Disease. In both analyses RDW exhibited 
a higher statistical association with outcome than 
conventional risk scores such as left ventricular 
ejection fraction (LVEF) and New York Heart Asso-
ciation (NYHA) functional class. Subsequent stud-
ies (including a meta-analysis) have confirmed the 
predictive role of RDW as a risk factor of short- and 
long-term mortality among patients with chronic 
and acute decompensated HF. However, patients 
in those studies were selected according to HF 
symptoms, Framingham criteria and NYHA class, 
irrespective of HF origin and LVEF values [9–14].
This study aimed to explore the relation-
ship between RDW at admission and all-cause, 
long-term mortality in a wide spectrum of pa-
tients hospitalized with a LVEF of ≤ 35% in the 
COnte Mporary Modalities In Treatment of Heart 
Failure (COMMIT-HF) registry maintained by the 
3rd Chair and Department of Cardiology of the Sile-
sian Center for Heart Diseases, Poland (Clinical-
Trials.gov Identifier: NCT01471522). It was also 
sought to establish whether RDW has the same 
prognostic value in patients with ischemic and non-
ischemic left ventricular systolic dysfunction (LVSD). 
Methods
Patient selection
The analyzed cohort consisted of a subset of 
patients in the COMMIT-HF registry, an ongoing 
project at this institution (the Silesian Center for 
Heart Diseases). The COMMIT-HF registry in-
cluded patients with LVEF of ≤ 35% without ACS 
[15, 16]. Baseline characteristics and in-hospital 
data were recorded on case report forms. Demo-
graphic data, concomitant diseases and laboratory 
parameters such as RDW are stored in this data-
base. All patients underwent LVEF assessment 
during the initial 24 h of the index hospitalization. 
The exclusion criterion was ACS. Additionally, we 
have excluded patients with serious concurrent 
systemic disease resulting in reduced life expec-
tancy (n = 64). A total of 1734 patients admitted 
to our institution were analyzed between January 
2009 and December 2013. Patients were divided 
into three groups according to baseline tertiles 
of RDW. Low, medium and high tertiles were de-
fined as RDW ≤ 13.4% (n = 569), 13.4% < RDW 
≤ 14.6% (n = 585) and RDW > 14.6% (n = 580), 
respectively. Survival analysis, stratified by RDW 
tertile, was used to evaluate the usefulness of 
RDW in predicting all-cause long-term mortality in 
the whole cohort and separately for patients with 
ischemic and non-ischemic LVSD. This investiga-
tion conforms to the principles outlined in the 
Declaration of Helsinki and has been approved by 
the Ethics Committee at the District Chamber of 
Physicians.
Blood sampling
Blood samples were obtained on admission 
and processed immediately. Complete blood counts 
were performed using the Sysmex XS1000i and 
XE2100 apparatus (Sysmex Corporation, Kobe, 
Japan). RDW was defined as the quotient of stand-
ard deviation (SD) of red blood cell volume and its 
mean volume and is expressed as a percentage 
according to the following formula: RDW = (SD of 
red blood cell volume / mean cell volume) × 100. 
Higher RDW values reflect greater variations in 
red blood cell volume. 
Follow-up data
The primary endpoint was death from any 
cause. Information on survival was based on the 
National Health Fund insurance status, which can 
be electronically verified as the National Health 
Fund insurance policy is compulsory for all Polish 
citizens. Insured patients were marked as alive. 
Complete follow-up data were available for the 
whole cohort.
Statistical analysis 
Continuous variables were presented as the 
mean and SD or median with interquartile range 
(IQR). Categorical variables were expressed as 
frequencies and percentages. The assumption of 
normality for continuous variables was verified via 
the Shapiro-Wilk test. Continuous variables were 
compared across RDW tertiles using analysis of 
variance or Kruskal-Wallis tests. Categorical vari-
ables were compared using c2 test.
Associations between RDW tertiles and 
mortality were analyzed using the Kaplan-Meier 
method with log-rank testing. Univariate and mul-
tivariate Cox regression models were utilized to 
evaluate the association between RDW tertiles and 
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mortality. The stepwise selection method of model 
building was used, with p-value set to 0.2 to allow 
a confounder into the model and P-value set to 0.1 for 
a confounder to stay in the model. N-terminal pro-
B-type natriuretic peptide (NT-proBNP) and blood 
urea nitrogen were not included in multivariable 
analysis because data on these parameters were 
available for only a minority of patients. Crude and 
adjusted hazard ratios (HR) with 95% confidence 
intervals (CI) were presented. Receiver-operating 
characteristic (ROC) curves were estimated for 
models with and without RDW. Areas under ROC 
curves (AUC) for these models were compared us-
ing logistic regression method. The interpretation 
of statistical significance was based on a value of 
a = 0.05. Statistical analyses were performed us-
ing the SAS statistical software package, version 
9.4 (SAS Institute Inc., Cary, North Carolina, USA) 
and the STATISTICA 10 software (StatSoft Inc., 
Tulsa, Oklahoma, USA).
Results
Baseline characteristics  
of the patient population
The study cohort consisted of 1734 patients 
with LVSD (1387 males), with a median age of 61.0 
years (IQR: 53.0÷71.0 years). Baseline clinical 
characteristics of the patients across RDW tertiles 
are presented in Table 1. Ischemic etiology was 
diagnosed in 370 (65.2%), 378 (65.6%) and 376 
(63.8%) subjects in low, medium and high RDW 
tertiles, respectively. A stepwise relationship was 
observed between RDW tertiles and co-morbid-
ities in the whole group. Subjects in the highest 
RDW tertile were significantly older, had a higher 
prevalence of anemia, atrial fibrillation and stage III 
or higher chronic kidney disease compared with 
patients in other tertiles. The patients in the 
highest RDW tertile also had a worse clinical 
status defined as higher NYHA functional class on 
admission. Echocardiographic parameters were 
unanimously inferior in the highest RDW tertile, 
with significantly lower LVEF, higher end-systolic 
and end-diastolic volumes as well as diameters, 
with a significantly higher occurrence of both 
mitral and aortic severe valve disease compared 
with patients in low and medium tertiles. Analysis 
of these findings revealed a stepwise relationship 
between RDW tertiles and lower hemoglobin con-
centration, higher bilirubin, blood urea nitrogen, 
creatinine, uric acid and N-proBNP titers. Total 
cholesterol levels were significantly lower across 
higher RDW tertiles. Significant differences were 
observed between some of the groups with regard 
to prescribed medical treatment. Patients in the 
highest tertile were less frequently treated with 
angiotensin-converting-enzyme inhibitors (ACEI), 
statins, b-blockers and received antiplatelet treat-
ment. In contrast, they presented more frequently 
with loop and thiazide diuretics, digoxin and oral 
anticoagulation treatments. 
Survival analysis
Follow-up data were available for the whole 
cohort. Median follow-up was 660 days (IQR 
331÷1074 days). The primary endpoint was all-
cause mortality. During the observation period, 
443 (25.5%) deaths were reported. The comparison 
of baseline characteristics between patients who 
survived and those who died during follow-up 
period is presented in Supplementary Table 1. 
In the whole cohort there was an almost 8-fold 
increase in all-cause 12-month mortality in high 
RDW tertile compared with low tertile (3.2% vs. 
24.0%, p < 0.01).
The analysis of crude HR revealed significant-
ly higher mortality for both medium (HR 1.9; 95% 
CI 1.4–2.5; p < 0.0001) and high RDW tertiles (HR 
4.3; 95% CI 3.3–5.7; p < 0.0001) in comparison 
to the lowest tertile. In Cox regression analysis, 
the highest RDW tertile was an independent fac-
tor related to higher long-term mortality (HR 2.8; 
95% CI 2.1–3.8; p < 0.0001), along with older age, 
diabetes and severe mitral insufficiency. Using 
RDW as a continuous variable, the adjusted HR for 
12-month mortality was 1.26 (95% CI 1.21–1.3). 
Higher LVEF and hemoglobin levels, and admin-
istration of ACEI and b-blockers, were shown to 
independently improve survival (Fig. 1). RDW 
> 14.6% (high teritle cut-off) had sensitivity 
of 0.55 (95% CI 0.51–0.59) and specificity of 
0.74 (95% CI 0.72–0.76) in predicting all-cause 
mortality in the whole patient cohort. AUC for 
model with RDW was significantly higher than for 
model without RDW (Suppl. Fig. 1 and Table 2). 
Kaplan-Meier survival curves across RDW ter-
tiles are presented in Figure 2. 
Kaplan-Meier curves in the ischemic LVSD 
etiology subgroup reveal significant differences in 
mortality across RDW tertiles (Fig. 2). This was 
confirmed by the Cox regression analysis, where 
high RDW tertile was an independent factor related 
to higher long-term mortality (HR 2.8; 95% CI 
2.0–3.9; p < 0.0001) (Fig. 3). Results of the analysis 
were similar in the whole population, with anemia, 
prior stroke and higher heart rate were also identi-
fied as factors impairing prognosis.
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Table 1. Baseline clinical characteristics of the studied population grouped according to red blood cell 
distribution width (RDW) tertiles.
Clinical characteristics RDW tertile P
Low (n = 569) 
RDW £ 13.4%
Medium (n = 585) 
13.4% < RDW £ 14.6%
High (n = 580) 
RDW > 14.6%
Age [years]a 58.9 ± 12.7 61.9 ± 12.8 61.7 ± 12.5 < 0.001
Womena 19.5% 21.9% 18.7% 0.4
Body mass index [kg/m2]a 27.9 ± 4.3 27.8 ± 5.2 27.2 ± 5.0 0.05
Diabetes mellitusa 37.6% 38.1% 47.9% < 0.01
Hypertensiona 53.5% 51.3% 49.5% 0.4
Anemiaa 26.4% 31.6% 50.3% < 0.01
Previous myocardial infarctiona 50.1% 45.8% 46.6% 0.3
Previous PCIa 23.9% 21.0% 14.8% < 0.01
Previous strokea 4.9% 6.5% 8.3% 0.1
Chronic kidney disease stage III+a 20.6% 25.6% 40.5% < 0.01
eGFR [mL/min/1.73 m2]a 80.8 (63.8–97.4) 75.4 (59.4–94.5) 67.5 (49.5–89.0) < 0.001
Atrial fibrillationa 20.2% 35.2% 44.1% < 0.01
NYHA class on admissiona < 0.001
I 17.6% 11.5% 8.3%
II 42.2% 37.1% 25.3%
III 35.3% 41.5% 48.5%
IV 4.9% 9.9% 17.9%
Hospitalization due to symptoms  
of acute heart failurea
11.6% 17.0% 16.6% 0.018
Systolic BP [mmHg]a 127.4 ± 21.3 124.3 ± 21.6 119.5 ± 22.4 < 0.001
Diastolic BP [mmHg]a 78.1 ± 13 76.6 ± 13.1 74 ± 13.7 < 0.001
Heart rate [bpm]a 76.5 ± 16.3 79.6 ± 20.1 80.6 ± 18.9 < 0.001
RDW [%]a 12.9 ± 0.4 14.0 ± 0.3 16.5 ± 2 < 0.001
Hemoglobin [mmol/L]a 8.9 ± 1 8.7 ± 1.1 8.1 ± 1.2 < 0.001
MCHC [mmol/L]a 21.26 ± 0.61 21.03 ± 0.62 20.71 ± 0.75 < 0.001
White blood cell count [× 103/µL]a 7.6 ± 2.3 7.9 ± 2.7 7.8 ± 2.7 0.2
Bilirubin [µmol/L]b 13.3 ± 9.1 15.9 ± 17.2 19 ± 13.3 < 0.001
Blood urea nitrogen [mmol/L]c 8.4 ± 4.5 8.9 ± 4.6 11.9 ± 7.9 < 0.001
Creatinine [µmol/L]a 93.4 ± 36.5 95.7 ± 38.2 117.3 ± 86.6 < 0.001
NT-proBNP [pg/mL]d 699 (274.7–1855.0) 1891 (942.3–3861.0) 3260 (1420–6476) < 0.001
Cholesterol [mmol/L]e 4.7 ± 1.3 4.8 ± 3 4.2 ± 1.3 < 0.001
Uric acid [µmol/L]f 411.5 ± 115 436.2 ± 125.1 463.4 ± 149.9 < 0.001
ACEIa 78.2% 73.3% 69.0% < 0.01
ARBa 7.9% 7.1% 7.1% 0.8
Beta-blockersa 97.5% 94.9% 93.9% 0.01
Diuretics (loop and thiazide)a 80.7% 84.1% 88.3% < 0.01
MRAa 85.9% 84.3% 81.6% 0.1
Statinsa 79.8% 76.6% 67.7% < 0.01
Digoxina 15.5% 22.9% 31.9% < 0.01
Calcium-blockersa  8.8% 8.0% 7.7% 0.8
Antiplatelet treatmenta 73.1% 71.8% 65.4% < 0.01
Oral anticoagulationa 23.4% 36.6% 43.0% < 0.01
Æ
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In the non-ischemic etiology group, Kaplan-
Meier analysis revealed significant differences in 
survival between subsequent RDW tertiles (Fig. 2). 
The influence of RDW was again confirmed in this 
subpopulation by Cox regression analysis (HR 3.3; 
95% CI 2.0–5.5; p < 0.0001) (Fig. 4).
Discussion
The primary finding of  this study was that 
baseline RDW appeared to be a strong, positive 
risk factor for all-cause mortality in long-term 
follow-up of patients with a LVEF of 35% or less. 
An increased RDW was significantly associated 
with worse long-term outcome in subgroups of both 
ischemic and non-ischemic LVSD. The prognostic 
value of RDW was significant after adjusting for 
known confounders including comorbid conditions 
and treatments. To our knowledge, this analysis 
represents the first report of elevated RDW as 
a robust prognostic marker of all-cause mortality in 
patients hospitalized with a LVEF of 35% or less. 
Table 1 (cont.). Baseline clinical characteristics of the studied population grouped according to red 
blood cell distribution width (RDW) tertiles.
Clinical characteristics RDW tertile P
Low (n = 569) 
RDW £ 13.4%
Medium (n = 585) 
13.4% < RDW £ 14.6%
High (n = 580) 
RDW > 14.6%
Insulina 14.5% 12.7% 18.1% 0.04
Ischemic etiologya 65.2% 65.6% 63.8% 0.8
Valvular etiologya 4.9% 8.9% 12.9% < 0.01
Other etiologya 30.3% 23.7% 24.5% 0.04
LV ejection fraction [%]a 27.4 ± 5.5 26.4 ± 5.9 24.3 ± 6.5 < 0.001
LV end systolic diameter [mm]a 51.5 ± 9.8 52.2 ± 10.4 54.8 ± 11.6 < 0.001
LV end diastolic diameter [mm]a 64.2 ± 8.3 64.6 ± 9.3 66.3 ± 10.3 < 0.001
LV end systolic volume [mL]a 144.4 ± 66.3 152.9 ± 68.7 162.8 ± 83.2 0.003
LV end diastolic volume [mL]a 195.1 ± 75.4 204.5 ± 82.3 213.6 ± 98.6 0.01
Severe mitral insufficiencya 7.6% 11.6% 20.9% < 0.01
Severe aortic valve  
insufficiency/stenosisa
2.3% 5.3% 9.1% < 0.01
All-cause 12-month mortalitya 3.2% 10.1% 24.0% < 0.01
Continuous variables are presented as median (interquartile range) or mean ± standard deviation. Dichotomic variables are presented as 
percentage. Data available for: a100% of patients; b97.9% of patients; c39.6% of patients; d18.1% of patients; e87.3% of patients; f88.5% of 
patients; ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin receptor blockers; BP — blood pressure; eGFR — estimated 
glomerular filtration rate; LV — left ventricular; MRA — mineralocorticoid receptor antagonists; MCHC — mean corpuscular hemoglobin 
concentration; NT-proBNP — N-terminal pro-B-type natriuretic peptide; NYHA — New York Heart Association; PCI — percutaneous coronary 
intervention
Figure 1. Predictors of mortality. Adjusted hazard ratio for the following parameters: older age (per 1 year increase), 
heart rate (per 1 bpm increase), hemoglobin on admission (per 1 mmol/L increase), left ventricular ejection fraction 
(LVEF) (per 1% increase); ACEI — angiotensin-converting enzyme inhibitors; CI — confidence interval;  RDW — red 
cell distribution width.
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Elevated RDW had been shown to predict 
poor outcomes in the normal population [17, 18], 
in patients with CAD [2–6], and in patients with 
HF [10–14]. The present analysis is the first to 
demonstrate the predictive value of RDW both in 
patients with ischemic and non-ischemic LVSD. 
The results of this analysis are in line with re-
sults of recently published studies. Sargento [19] 
showed that high RDW is associated with worse 
outcomes in optimally medicated HF outpatients 
with reduced LVEF. Furthermore Bozorgi et al. [20] 
demonstrated that RDW predicts the presence of 
severe LVSD in post myocardial infarction patients. 
In contrast, Sotiropoulos et al. [21] reported that 
high RDW is associated with long-term mortality in 
patients with preserved, but not reduced ejection 
fraction. The results of prospective studies with 
long-term follow-up (Tromsø and National Health 
and Nutrition Examination Survey) demonstrate 
that high RDW values are associated with increased 
risk of myocardial infarction and mortality due to 
CAD in the general population [17, 18], and in 
elderly patients without age-associated diseases 
[22]. Tonelli et al. [4] have shown that RDW is 
a risk factor for myocardial infarction, stroke and 
symptomatic HF in patients with stable CAD. 
A meta-analysis performed by Patel et al. [22] in 
older adults revealed that RDW was a powerful 
predictor of mortality in community-dwelling 
older adults. In this analysis, a distinct gradient 
in mortality risk associated with increasing RDW 
was reported: for every 1% increase in RDW, the 
risk of death increased by 14% [22]. Additionally, 
a meta-analysis by Huang et al. [11] confirmed 
that in patients with HF, increased RDW either at 
baseline or at discharge, as well as changes in RDW 
during treatment, were associated with poor prog-
nosis. In this analysis, all-cause mortality increased 
by 10% with each 1% increase in baseline RDW [11]. 
In our study, every 1% increment in RDW increased 
all-cause mortality by 18.3% (95% CI 12.3–24.7%) in 
the group of patients with ischemic LVSD and 25.1% 
(95% CI 17.3–33.4%) in non-ischemic LVSD patients.
Mechanisms underlying the relationship be-
tween RDW and poor outcome are not fully under-
stood. A variety of mechanisms have been proposed 
for the associations among cardiovascular disease, 
HF, RDW and outcomes. It is difficult to determine 
whether RDW is only an epiphenomenon of various 
concomitant disorders or if it is directly responsible 
for poor prognosis. It is possible that RDW may 
impact mortality through mechanisms unrelated to 
anemia and iron status. A high RDW is associated 
with increased mortality in patients with HF regard-
less of baseline hemoglobin level [10, 12]. RDW 
has also been shown to possess prognostic value in 
non-anemic patients [23]. However, Pascual-Figal 
et al. [24] have identified RDW as a predictor of the 
development of new-onset anemia over a 6-month 
follow-up period in non-anemic patients with decom-
pensated HF. Not surprisingly, RDW is affected by 
iron metabolism status [25]. Jankowska et al. [26] 
have indicated that disturbances in iron metabolism 
are associated with mortality in patients with HF.
Figure 2. Kaplan-Meier plot showing crude cumulative 
incidence of all-cause death depending on tertiles of 
admission red cell distribution width (RDW) in the en-
tire group (A), the ischemic (B) and the non-ischemic (C) 
subpopulation.
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Another explanation for the relationship 
between RDW and outcomes may be chronic in-
flammation. Inflammation, even of low intensity, 
may play a crucial role in atherogenesis and HF 
[27]. Previous studies have demonstrated a rela-
tionship between RDW and indicators of inflam-
mation such as erythrocyte sedimentation rate, 
high sensitivity C-reactive protein, fibrinogen, 
interleukin-6, soluble tumor necrosis factor (TNF) 
receptor I and soluble TNF receptor II [25, 28, 29]. 
Additionally, chronic inflammation leads to distur-
bances in iron metabolism and an impaired bone 
marrow response to erythropoietin, increasing 
the RDW value [29, 30]. Chronic inflammation is 
often observed in patients with chronic kidney dis-
ease [27, 31]. Lippi et al. [32] have demonstrated 
a significant association between high RDW and 
impaired renal function.
It has been shown that oxidative stress is re-
sponsible for shortening the lifespan of RBC, thus 
increasing the production and release of young cells 
into circulation, which is reflected in an increased 
RDW [33]. Oxidative stress also generates oxidized 
low density lipoprotein, which plays an important 
role in atherogenesis [34]. 
The above-mentioned mechanisms indicate 
a correlation between RDW and other known risk 
factors, although it is impossible to clearly identify 
the exact mechanism by which high erythrocyte 
anisocytosis is a negative prognostic marker in 
patients with CAD and HF. In our opinion, the prog-
nostic value of RDW derives mainly from the nega-
tive impact of inflammation, oxidative stress, and 
iron deficiency on bone marrow erythropoiesis in 
patients with LVSD. Nonetheless, RDW routinely 
measured as a part of whole blood count, could be 
an inexpensive and robust biomarker, that would be 
useful in risk stratification in patients with LVSD.
Limitations of the study
A limitation of the current study is that it was 
a single-center observational study with inherent 
weakness related to retrospective analysis. A sin-
gle blood sample was used at admission to calculate 
RDW and this study included all-cause mortality 
as the endpoint. Data regarding nutritional status, 
Figure 4. Predictors of mortality in patients with non-ischemic left ventricular systolic dysfunction. Adjusted hazard 
ratio for left ventricular ejection fraction (LVEF) (per 1% increase); ACE — angiotensin-converting enzyme inhibitors; 
CI — confidence interval; RDW — red cell distribution width.
Figure 3. Predictors of mortality in the subpopulation of patients with ischemic left ventricular systolic dysfunction. 
Adjusted hazard ratio for the following parameters: older age (per 1 year increase), heart rate (per 1 bpm increase), 
left ventricular ejection fraction (LVEF) (per 1% increase); CI — confidence interval; RDW — red cell distribution width; 
ICD — implantable cardioverter-defibrillator
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such as iron plasma concentration, deficits of fo-
lic acid, vitamin B12, erythropoietin, ferritin and 
reticulocyte levels were not included. Moreover, 
current NT-proBNP titers were available only for 
a limited subset of patients (18.1%). Strengths of 
this study include a large patient cohort, detailed 
data on clinical, echocardiography and laboratory 
parameters, a long follow-up period and no patients 
lost to follow-up.
Conclusions
In this study RDW was a robust predictor of 
long-term mortality in patients hospitalized with 
a LVEF of ≤ 35%, independently of LVSD etiology. 
Further investigations are needed to outline the 
exact underlying pathophysiology of poor out-
comes in patients with LVSD and high erythrocyte 
anisocytosis. 
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